Researchers have developed PL@mBiME, an innovative lipid nanoparticle platform designed to treat glioblastoma through dual immunotherapy mechanisms. This system delivers mRNA encoding a bispecific macrophage engager that simultaneously targets tumor cells and reprograms immunosuppressive macrophages toward pro-inflammatory states, while also releasing PD-L1 antibodies to enhance adaptive immunity. The platform utilizes tumor-responsive features including pH-sensitive charge reversal for improved brain tumor accumulation and glutathione-triggered antibody release. Across multiple glioblastoma models, this coordinated activation of innate and adaptive immunity achieved significant tumor regression, extended survival, and durable immune memory without notable toxicity, offering a promising approach to overcome limitations of conventional immunotherapies in solid tumors.

Gliomas represent biologically distinct subtypes with varying clinical outcomes and immune microenvironments, with IDH-wildtype glioblastoma being the most aggressive form. Despite immunotherapy's success in other solid tumors, its efficacy in glioma remains limited due to a profoundly immunosuppressive tumor microenvironment. This comprehensive review examines the establishment and regulatory mechanisms underlying glioma's immunosuppressive state, detailing global immune characteristics and critical cellular and molecular foundations. The analysis emphasizes the myeloid-cell network, particularly tumor-associated macrophages, while identifying key biomarkers and emerging immunotherapeutic strategies aimed at reshaping the immunosuppressive microenvironment to enhance treatment outcomes.

GeoVax Labs has filed a resale registration statement covering 865,804 warrant shares, raising significant concerns among investors regarding the company's financial viability. The clinical-stage biopharmaceutical firm, focused on vaccines and immunotherapies for infectious diseases and cancers, faces material risks including substantial operating losses of approximately $21.5 million and a going concern warning from auditors. With existing cash expected to sustain operations only through mid-second quarter 2026, GeoVax confronts critical financing challenges. Additionally, the company faces potential Nasdaq delisting risks due to quantitative listing triggers and significant shareholder dilution from warrant and option overhang. These combined pressures underscore the urgent need for successful financing or strategic partnerships to ensure long-term viability.

GeoVax Labs completed a warrant inducement transaction with institutional investors, generating approximately $595,000 in gross proceeds through the immediate exercise of existing warrants for 501,144 common shares. In exchange, investors received new unregistered warrants to purchase up to 1,002,288 additional shares at an exercise price of $1.65 per share. The new warrants will become exercisable following shareholder approval and expire five years thereafter. A.G.P./Alliance Global Partners served as the exclusive financial advisor, receiving a 7.0% cash fee on proceeds and up to $40,000 in legal expense reimbursement. This transaction represents a material strategic capital-raising initiative reported through an 8-K SEC filing.

Our results demonstrate that targeted PNP-GDEPT has the potential to enhance the efficacy of chemotherapy and targeted therapy against ovarian cancer while minimizing side effects on healthy cells. This treatment is effective irrespective of cisplatin resistance status and warrants further investigation.

Recent progress in material science has led to the development of new drug delivery systems that go beyond the conventional approaches and offer greater accuracy and convenience in the application of therapeutic agents. This review discusses the evolutionary role of nanocarriers, hydrogels, and bioresponsive polymers that offer enhanced drug release, target accuracy, and bioavailability. Oncology, chronic disease management, and vaccine delivery are some of the applications explored in this paper to show how these materials improve the therapeutic results, counteract multidrug resistance, and allow for sustained and localized treatments. The review also discusses the translational barriers of bringing advanced materials into the clinical setting, which include issues of biocompatibility, scalability, and regulatory approval. Methods to overcome these challenges include surface modifications to reduce immunogenicity, scalable production methods such as microfluidics, and the harmonization of regulatory systems. In addition, the convergence of artificial intelligence (AI) and machine learning (ML) is opening new frontiers in material science and personalized medicine.

Cancer is a significant global socioeconomic burden, as millions of new cases and deaths occur annually. In 2020, almost 10 million cancer deaths were recorded worldwide. Advancements in cancer gene therapy have revolutionized the landscape of cancer treatment. An approach with promising potential for cancer gene therapy is introducing genes to cancer cells that encode for chemotherapy prodrug metabolizing enzymes, such as Cytochrome P450 (CYP) enzymes, which can contribute to the effective elimination of cancer cells. This can be achieved through gene-directed enzyme prodrug therapy (GDEPT). CYP enzymes can be genetically engineered to improve anticancer prodrug conversion to its active metabolites and to minimize chemotherapy side effects by reducing the prodrug dosage. Rational design, directed evolution, and phylogenetic methods are some approaches to developing tailored CYP enzymes for cancer therapy. Here, we provide a compilation of genetic modifications performed on CYP enzymes aiming to build highly efficient therapeutic genes capable of bio-activating different chemotherapeutic prodrugs. Additionally, this review summarizes promising preclinical and clinical trials highlighting engineered CYP enzymes’ potential in GDEPT. Finally, the challenges, limitations, and future directions of using CYP enzymes for GDEPT in cancer gene therapy are discussed.

High-grade glioma is one of the deadliest primary tumors of the central nervous system. Despite the many novel immunotherapies currently in development, it has been difficult to achieve breakthrough results in clinical studies. The reason may be due to the suppressive tumor microenvironment of gliomas that limits the function of specific immune cells (e.g., T cells) which are currently the primary targets of immunotherapy. However, tumor-associated macrophage, which are enriched in tumors, plays an important role in the development of GBM and is becoming a research hotspot for immunotherapy. This review focuses on current research advances in the use of macrophages as therapeutic targets or therapeutic tools for gliomas, and provides some potential research directions.

Oncolytic virotherapy can lead to tumor lysis and systemic anti-tumor immunity, but the therapeutic potential in humans is limited due to the impaired virus replication and the insufficient ability to overcome the immunosuppressive tumor microenvironment (TME). To solve the above problems, we identified that Indoleamine 2, 3-dioxygenase 1 (IDO1) inhibitor Navoximod promoted herpes simplex virus type 1 (HSV-1) replication and HSV-1-mediated oncolysis in tumor cells, making it a promising combination modality with HSV-1-based virotherapy. Thus, we loaded HSV-1 and Navoximod together in an injectable and biocompatible hydrogel (V-Navo@gel) for hepatocellular carcinoma (HCC) virotherapy. The hydrogel formed a local delivery reservoir to maximize the viral replication and distribution at the tumor site with a single-dose injection. Notably, V-Navo@gel improved the disease-free survival time of HCC- bearing mice and protects the mice against tumor recurrence. What’s more, V-Navo@gel also showed an effective therapeutic efficacy in the rabbit orthotopic liver cancer model. Mechanistically, we further discovered that our combination strategy entirely reprogramed the TME through single-cell RNA sequencing. All these results collectively indicated that the combination of Navoximod with HSV-1 could boost the viral replication and reshape TME for tumor eradication through the hydrogel reservoir.

The sol–gel chemistry of silica has long been used for manipulating the size, shape, and microstructure of mesoporous silica particles. This manipulation is performed in mild conditions through controlling the hydrolysis and condensation of silicon alkoxide. Compared to amorphous silica particles, the preparation of mesoporous silica, such as MCM-41, using the sol–gel approach offers several unique advantages in the fields of catalysis, medicament, and environment, due to its ordered mesoporous structure, high specific surface area, large pore volume, and easily functionalized surface. In this review, our primary focus is on the latest research related to the manipulation of mesoporous silica architectures using the sol–gel approach. We summarize various structures, including hollow, yolk-shell, multi-shelled hollow, Janus, nanotubular, and 2D membrane structures. Additionally, we survey sol–gel strategies involving the introduction of various functional elements onto the surface of mesoporous silica to enhance its performance. Furthermore, we outline the prospects and challenges associated with mesoporous silica featuring different structures and functions in promising applications, such as high-performance catalysis, biomedicine, wastewater treatment, and CO2 capture.

Liver cancer has high incidence and mortality rates and its treatment generally requires the use of a combination treatment strategy. Therefore, the early detection and diagnosis of liver cancer is crucial to achieving the best treatment effect. In addition, it is imperative to explore multimodal combination therapy for liver cancer treatment and the synergistic effect of two liver cancer treatment drugs while preventing drug resistance and drug side effects to maximize the achievable therapeutic effect. Gold nanoparticles are used widely in applications related to optical imaging, CT imaging, MRI imaging, biomarkers, targeted drug therapy, etc., and serve as an advanced platform for integrated application in the nano-diagnosis and treatment of diseases. Dual-drug-delivery nano-diagnostic and therapeutic agents have drawn great interest in current times. Therefore, the present report aims to review the effectiveness of dual-drug-delivery nano-diagnostic and therapeutic agents in the field of anti-tumor therapy from the particular perspective of liver cancer diagnosis and treatment.

Most targeted anticancer therapies fail due to drug resistance evolution. Here we show that tumor evolution can be reproducibly redirected to engineer therapeutic opportunity, regardless of the exact ensemble of pre-existing genetic heterogeneity. We develop a selection gene drive system that is stably introduced into cancer cells and is composed of two genes, or switches, that couple an inducible fitness advantage with a shared fitness cost. Using stochastic models of evolutionary dynamics, we identify the design criteria for selection gene drives. We then build prototypes that harness the selective pressure of multiple approved tyrosine kinase inhibitors and employ therapeutic mechanisms as diverse as prodrug catalysis and immune activity induction. We show that selection gene drives can eradicate diverse forms of genetic resistance in vitro.

Recent progress in material science has led to the development of new drug delivery systems that go beyond the conventional approaches and offer greater accuracy and convenience in the application of therapeutic agents. This review discusses the evolutionary role of nanocarriers, hydrogels, and bioresponsive polymers that offer enhanced drug release, target accuracy, and bioavailability. Oncology, chronic disease management, and vaccine delivery are some of the applications explored in this paper to show how these materials improve the therapeutic results, counteract multidrug resistance, and allow for sustained and localized treatments.

Mesenchymal stem cells loaded with chemotherapeutic drugs show improved penetration and tumor accumulation. For gene therapy, mesenchymal stem cells can be used as vehicles for suicide genes, the so-called gene-directed enzyme prodrug therapy. Mesenchymal stem cell-based oncolytic viral therapies have been attempted in recent years to enhance the efficacy of infection against the tumor, viral replication, and distribution of viral particles. Many uncertainties remain regarding the function and behavior of mesenchymal stem cells in gliomas. However, strategies to increase mesenchymal stem cell migration to gliomas may improve the delivery of therapeutic agents and enhance their anti-tumor effects, representing promising potential for patient treatment.

The packaging is described as a food-grade film predominantly made from algae-based ingredients. It is designed to package and protect products like rice, pasta, ramen, oats, frozen vegetables, and pre-prepared outdoor meals. It can be washed in cold or warm water before use, ‘just like you’d wash a tomato’. Then it can be placed in boiling water, where the film dissolves ‘within a few minutes’ while the food cooks.

Cupffee has designed the ‘world’s first’ edible coffee cup, designed to avoid pollution and reduce CO2 emissions while performing as effectively as its single-use plastic counterparts.

While the cellophane wrapper used for Babybel products has reportedly been biobased and home-compostable since late 2020, the Bel Group has undertaken factory trials and real-world validation to develop its paper packaging in line with industrial performance requirements for large-scale production across its global facilities.

Les personnes atteintes d’Alzheimer oublient souvent de boire… mais raffolent des sucreries. Partant de ce constat, un jeune inventeur a imaginé les Jelly Drops : des bonbons sans sucre composés à 95% d’eau et enrichis en électrolytes. Colorés, ludiques et faciles à consommer, ils permettent aux malades de rester hydratés sans effort, notamment en période de forte chaleur.

Et si le fromage pouvait s’emballer lui-même ? C’est l’idée un peu folle – mais bien réelle – imaginée par Nestlé en collaboration avec l’agence Ogilvy Colombia. Baptisé Self-Packing Cheese, ce projet expérimental transforme un sous-produit laitier souvent jeté, le petit-lait, en un emballage biodégradable capable de protéger… du fromage.

Medirest, spécialiste de l’alimentation médicale, dévoile une nouvelle version de Mix&Délices, une solution culinaire dédiée aux personnes souffrant de troubles de la mastication et de la déglutition. Fruit d’un an et demi de recherche et de développement, cette initiative incarne l’alliance réussie entre expertise médicale, scientifique et culinaire.